Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Xoma and Pfizer discontinue U.S. phase III trial of E5

April 28, 1997

Potent TNF inhibitor described by Celgene

April 28, 1997

Novel marine antioxidant described by UNC researchers

April 25, 1997

New alpha1-adrenoceptor antagonist evaluated

April 25, 1997

Endothelin antagonists disclosed by BASF

April 24, 1997

Comparison of aspirin and pentoxifylline for claudication

April 23, 1997

Balanced ETA/ETB antagonist from Abbott

April 22, 1997

Merck KGaA prepares cardioprotective agents

April 22, 1997

PGE1 derivatives for peripheral circulatory disorders from Ono

April 22, 1997

Teva receives FDA approval for antihypertensive generic

April 22, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.